Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III TrialPaul E. Goss, Lois E. Shepherd, George W. Sledge et al.|Journal of Clinical Oncology|2013Cited by 261
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase InhibitorsJames N. Ingle, Richard M. Weinshilboum, Daniel J. Schaid et al.|Journal of Clinical Oncology|2010Cited by 212